|
|
|
|
| LEADER |
00000cam a2200000Ii 4500 |
| 001 |
SCIDIR_on1299142849 |
| 003 |
OCoLC |
| 005 |
20231120010634.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
220224s2022 enk o 000 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|e rda
|e pn
|c YDX
|d ABC
|d OPELS
|d GZM
|d OCLCO
|d OCLCF
|d UKMGB
|d SFB
|d OCLCQ
|
| 015 |
|
|
|a GBC256669
|2 bnb
|
| 016 |
7 |
|
|a 020528561
|2 Uk
|
| 019 |
|
|
|a 1298851485
|a 1298882449
|a 1298936607
|
| 020 |
|
|
|a 9780128232743
|q (electronic bk.)
|
| 020 |
|
|
|a 0128232749
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128222874
|
| 020 |
|
|
|z 0128222875
|
| 035 |
|
|
|a (OCoLC)1299142849
|z (OCoLC)1298851485
|z (OCoLC)1298882449
|z (OCoLC)1298936607
|
| 050 |
|
4 |
|a QP623.5.S63
|
| 082 |
0 |
4 |
|a 572.8/8
|2 23
|
| 245 |
0 |
0 |
|a MicroRNA in human malignancies /
|c editors, Massimo Negrini, George A. Calin, and Carlo M. Croce.
|
| 264 |
|
1 |
|a London :
|b Elsevier,
|c 2022.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 505 |
0 |
|
|a Intro -- MicroRNA in Human Malignancies -- Copyright -- Contents -- Contributors -- Section A: miRNAs involvement in basic mechanisms of cancer development -- Chapter 1 Overview on miRNA classification, biogenesis, and functions -- Introduction -- MicroRNA and the complex biological system of gene expression -- MicroRNA biogenesis, nomenclature, and classification -- Origins of the canonical primary miRNA transcript -- From canonical primary miRNA to mature miRNA -- Noncanonical miRNA biogenesis and isomiRs -- Nomenclature and classification -- Mechanisms of miRNA-mediated gene regulation -- Posttranscriptional regulation of mRNA stability and translation -- Models of miRNA-mediated gene regulation within the nucleus -- The dynamics of miRNA-mediated gene regulation -- MicroRNA abundance and turnover -- Concluding remarks -- References -- Chapter 2 microRNA in cancer: An overview -- The dawn of miRNAs in human biology -- First reported miRNA cancer-associated alterations -- The age of discovery: Microarrays and miRNA cancer signatures -- Functional classification of miRNA: The line between tumor suppressor and oncomiRs -- Development of miRNA as biomarkers -- The transition of miRNA into clinics -- Conclusion and future perspectives -- References -- Chapter 3 miR-15/16 in human malignancies -- 13q deletions in CLL and miR-15/16 -- Other mechanisms of miR-15/16 dysregulation -- Interplay between ROR1, Bcl2, and miR-15/16 in CLL -- miR-15/16 in mice -- miR-15/16 in human AML and MDS -- miR-15/16 in solid cancers -- References -- Chapter 4 microRNAs and tumor suppressor p53 regulation -- p53 and its signaling pathway -- GOF mutant p53 in cancer -- miRNAs regulated by wild-type p53 -- miRNAs that directly regulate p53 -- miRNAs that indirectly regulate p53 -- miRNAs regulated by GOF mutp53 -- Conclusion -- References.
|
| 505 |
8 |
|
|a Chapter 5 MicroRNA involvement in invasion and metastasis -- Introduction-The process of metastasis -- Direct regulation of metastasis -- Metastasis-promoting miRNAs -- Metastasis-Suppressing miRNAs -- Indirect regulation of metastasis -- Regulation of miRNA biosynthesis -- RNA-RNA interaction-based miRNA regulation -- Translational application of metastasis-associated miRNAs -- Noninvasive biomarkers -- miRNAs as therapeutics -- Conclusions and perspectives -- Acknowledgment -- References -- Chapter 6 microRNAs and metabolism -- Introduction -- Trafficking and consumption of glucose -- NcRNAs regulate glucose trafficking in cancer cells by altering GLUT levels -- NcRNAs regulate key glycolytic enzymes -- Branched pathways of glycolysis -- NcRNAs can influence glucose metabolism by regulating cancer-associated signaling pathways -- PI3K/Akt/mTOR and HIF-1 signaling pathway -- p53 signaling pathway -- Conclusion and future perspectives -- References -- Chapter 7 microRNAs in inflammation processes -- Introduction -- MiRNA biogenesis and functions -- Inflammation and mechanism of activation -- miRNAs in inflammatory disease -- Chronic respiratory diseases -- Cystic fibrosis (CF) -- Chronic obstructive pulmonary disease (COPD) -- Asthma -- Cardiovascular diseases -- Atherosclerosis -- Myocardial infarction (MI) and ischemia reperfusion injury (MIRI) -- Autoimmune diseases -- Systemic lupus erythematosus (SLE) -- Rheumatoid arthritis (RA) -- Multiple sclerosis (MS) -- Cancer -- Colorectal cancer (CRC) -- Lung cancer (LC) -- Prostate cancer (PC) -- Conclusion -- References -- Section B: miRNAs methodologies -- Chapter 8 Wet-lab methods for miRNA analysis -- Introduction -- Methods for miRNA discovery and detection -- Northern blot -- Hybridization microarrays -- Quantitative PCR -- Next-generation sequencing -- Functional miRNA analysis.
|
| 505 |
8 |
|
|a Classical target validation methods: Reporter genes and RISC immunoprecipitation -- High-throughput methods for target identification -- Functional validation -- Final remarks -- Acknowledgments -- References -- Chapter 9 Bioinformatics utilities, web resources and integrative strategies for the analysis of miRNA regulatory networks -- Introduction -- Target prediction algorithms -- Single predictors -- Multiple predictors -- In silico functional assessment of miRNAs: Tips and tricks -- Functional analysis of miRNAs associated with survival time in lung adenocarcinoma: A test case -- Conclusions -- Acknowledgments -- References -- Chapter 10 Computational resources for analysis of miRNA targetome -- Introduction -- miRNA target databases -- miRNA target databases for human -- miRNA target databases for other species -- miRNA algorithms -- miRNA target prediction for humans -- miRNA target prediction for other species -- miRNA target prediction for plants -- Conclusion -- References -- Chapter 11 miRNA bioinformatics and pathway analysis -- The microRNA synergy -- Role of microRNAs in biological signaling pathways -- Pathways: The manually curated maps of the cell interactome -- The miRNA interactome -- miRNA pathway analysis methods -- ORA on miRNA targets -- FCS on miRNA targets -- Topological approaches of pathway analysis with miRNAs -- Computational tools for miRNA pathway analyses -- Conclusions -- Funding -- References -- Section C: miRNAs involvement in therapeutics/theranostics -- Chapter 12 Opportunities of miRNAs in cancer therapeutics -- Introduction -- MicroRNAs in cancer. OncomiRs and tumor-suppressor miRNAs -- Alterations in miRNAs and their appeal for cancer therapy -- MicroRNA-based drug design -- Choosing the therapeutic strategy: miRNA mimics, antagomiRs, and more -- Chemical modifications of RNA-based drugs.
|
| 505 |
8 |
|
|a Delivery of RNA-based drugs -- Chemical modifications -- Liposomes, micelles, and exosomes -- Nanoparticles -- Viral vectors -- Bacteria-based vectors (EDV nanocells) -- MicroRNA-based therapeutics in the current clinic -- MRX34 -- Cobomarsen -- TargomiRs -- Remlarsen -- Other preclinical studies -- The future of miRNAs in the clinic -- Current challenges in the use of miRNAs -- Quick degradation in the bloodstream -- Extrahepatic delivery to tumor site -- Limited tissue penetration -- Endocytosis and endosome entrapment -- Off-targets and side effects -- Other challenges -- Future perspectives -- References -- Section D: miRNAs involvement in human cancer: Pathophysiology and translational opportunities -- Chapter 13 Pathophysiology roles and translational opportunities of miRNAs in acute leukemias -- Introduction -- MiRNAs involved in the pathogenesis of AML -- miRNAs as biomarkers -- miRNAs in chemoresistance -- miRNAs as therapeutic targets -- Role of miR-15/16 clusters in AML pathogenesis -- Conclusions -- References -- Chapter 14 Pathophysiology roles and translational opportunities of miRNAs in CLL -- MicroRNAs and the cellular origin of CLL cells -- MicroRNAs and CLL genetics -- microRNAs in proliferation and survival of CLL cells -- microRNAs and BCR signaling -- MicroRNAs and microenvironment -- MicroRNAs and apoptosis -- Translational opportunities -- References -- Chapter 15 Pathophysiology roles and translational opportunities of miRNAs in lymphoma -- Summary -- miRNAs and pathophysiology -- miRNAs regulate the expression of genes that promote B-cell differentiation -- Lymphomagenesis -- DLBCL and miRNA -- MZL and miRNA -- Diagnosis -- Prognosis -- References -- Chapter 16 Pathophysiology roles and translational opportunities of miRNAs in breast cancer -- Breast physiology and pathology -- Breast physiology -- Breast pathology.
|
| 650 |
|
0 |
|a MicroRNA.
|
| 650 |
|
2 |
|a MicroRNAs
|0 (DNLM)D035683
|
| 650 |
|
6 |
|a MicroARN.
|0 (CaQQLa)000265128
|
| 650 |
|
7 |
|a MicroRNA.
|2 fast
|0 (OCoLC)fst01940234
|
| 700 |
1 |
|
|a Negrini, Massimo.
|
| 700 |
1 |
|
|a Calin, George A.
|q (George Adrian)
|
| 700 |
1 |
|
|a Croce, Carlo M.
|
| 776 |
0 |
8 |
|c Original
|z 0128222875
|z 9780128222874
|w (OCoLC)1258782703
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128222874
|z Texto completo
|
